市場調查報告書

急性腎功能衰竭(ARF):市場考察,流行病學,市場預測 (2027年)

Acute Renal Failure (ARF) (Acute Kidney Injury) - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 524369
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
急性腎功能衰竭(ARF):市場考察,流行病學,市場預測 (2027年) Acute Renal Failure (ARF) (Acute Kidney Injury) - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年01月01日內容資訊: 英文 150 Pages
簡介

主要7個國家急性腎功能衰竭(ARF)的整體罹患數2016年151萬6,635人被推算,同年的急性腎功能衰竭市場估算為83億9,200萬美元。

本報告提供急性腎功能衰竭(ARF)市場相關調查,提供疾病概要,主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的市場趨勢,市場規模的變化與預測(過去2年·今後10年份),總括性彙整潛在成長性,促進·阻礙因素分析,開發中治療藥的簡介,目前未滿足需求等資訊。

目錄

第1章 主要考察

第2章 急性腎功能衰竭市場概要

  • 市場佔有率(實際成果值)
  • 市場佔有率(預測值)

第3章 疾病的背景和概要:急性腎功能衰竭(ARF)

  • 簡介
  • 症狀
  • 急性腎功能衰竭的種類
  • 病期分類
  • 風險因素
  • 病因
  • 病理學
  • 診斷
  • 管理

第4章 流行病學和患者人口

  • 主要的觀察
  • 人口與預測參數
  • 主要7個國家急性腎功能衰竭的罹患數
  • 主要7個國家急性腎功能衰竭的罹患數(實際成果值)
  • 主要7個國家急性腎功能衰竭的罹患數(預測值)

第5章 急性腎功能衰竭的流行病學

第6章 美國

  • 前提和根據
  • 美國的急性腎功能衰竭的罹患數
  • 美國的急性腎功能衰竭的住院數量:性別
  • 美國的急性腎功能衰竭的罹患數:各病期

第7章 歐盟5國

  • 前提和根據
  • 德國
    • 德國的急性腎功能衰竭的罹患數
    • 德國的急性腎功能衰竭的住院數量:性別
    • 德國的急性腎功能衰竭的罹患數:各病期
  • 法國
    • 法國的急性腎功能衰竭的罹患數
    • 法國的急性腎功能衰竭的住院數量:性別
    • 法國的急性腎功能衰竭的住院數量:各病期
  • 義大利
    • 義大利的急性腎功能衰竭的住院數量
    • 義大利的急性腎功能衰竭的住院數量:性別
    • 義大利的急性腎功能衰竭的住院數量:各病期
  • 西班牙
    • 西班牙的急性腎功能衰竭的住院數量
    • 西班牙的急性腎功能衰竭的住院數量:性別
    • 西班牙的急性腎功能衰竭的住院數量:各病期
  • 英國
    • 英國的急性腎功能衰竭的住院數量
    • 英國的急性腎功能衰竭的住院數量:性別
    • 英國的急性腎功能衰竭的住院數量:各病期

第8章 日本

  • 前提和根據
  • 日本的急性腎功能衰竭的住院數量
  • 日本的急性腎功能衰竭的住院數量:性別
  • 日本的急性腎功能衰竭的住院數量:各病期

第9章 治療和預防

第10章 全球開發中產品

第11章 新藥治療(臨床第三階段試驗)

  • EA-230:Exponential Biotherapies, Inc
    • 臨床開發
    • 臨床試驗資訊
    • 安全性和有效性
    • 優點與缺點
    • 產品簡介
  • Zemiglo:LG Life Sciences
  • RESCAP:Alloksys
  • BB3:Angion Biomedica
  • QPI-1002: Quark
  • recAP: AM Pharma

第12章 主要7個國家的急性腎功能衰竭(ARF)市場:市場規模

第13章 主要7個國家市場佔有率:新藥

第14章 主要7個國家市場佔有率:各國

第15章 主要7個國家市場佔有率:治療藥物別

  • 美國的急性腎功能衰竭(ARF)市場:市場規模
    • 美國的市場佔有率:新藥
  • 德國的急性腎功能衰竭(ARF)市場:市場規模
    • 德國的市場佔有率:新藥
  • 法國的急性腎功能衰竭(ARF)市場:市場規模
    • 法國的市場佔有率:新藥
  • 義大利的急性腎功能衰竭(ARF)市場:市場規模
    • 義大利的市場佔有率:新藥
  • 西班牙的急性腎功能衰竭(ARF)市場:市場規模
    • 西班牙的市場佔有率:新藥
  • 英國的急性腎功能衰竭(ARF)市場:市場規模
    • 英國的市場佔有率:新藥
  • 日本的急性腎功能衰竭(ARF)市場:市場規模
    • 日本的市場佔有率:新藥

第16章 治療費趨勢

第17章 市場成長要素

第18章 市場障礙

第19章 DelveInsight的服務內容

第20章 附錄

第21章 調查方法

第22章 免責聲明

第23章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0021

DelveInsight's "Acute Renal Failure (ARF) (Acute Kidney Injury) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Acute Renal Failure (ARF) (Acute Kidney Injury), historical and forecasted epidemiology as well as the Acute Renal Failure (ARF) (Acute Kidney Injury) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Acute Renal Failure (ARF) (Acute Kidney Injury) market report provides current treatment practices, emerging drugs, Acute Renal Failure (ARF) (Acute Kidney Injury) market share of the individual therapies, current and forecasted Acute Renal Failure (ARF) (Acute Kidney Injury) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Acute Renal Failure (ARF) (Acute Kidney Injury) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Acute Renal Failure (ARF) (Acute Kidney Injury) Disease Understanding and Treatment Algorithm

The DelveInsight Acute Renal Failure (ARF) (Acute Kidney Injury) market report gives a thorough understanding of the Acute Renal Failure (ARF) (Acute Kidney Injury) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Acute Renal Failure (ARF) (Acute Kidney Injury).

Treatment

It covers the details of conventional and current medical therapies available in the Acute Renal Failure (ARF) (Acute Kidney Injury) market for the treatment of the condition. It also provides Acute Renal Failure (ARF) (Acute Kidney Injury) treatment algorithms and guidelines in the United States, Europe, and Japan.

Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology

The Acute Renal Failure (ARF) (Acute Kidney Injury) epidemiology division provide insights about historical and current Acute Renal Failure (ARF) (Acute Kidney Injury) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Acute Renal Failure (ARF) (Acute Kidney Injury) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology

The epidemiology segment also provides the Acute Renal Failure (ARF) (Acute Kidney Injury) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Acute Renal Failure (ARF) (Acute Kidney Injury) Drug Chapters

Drug chapter segment of the Acute Renal Failure (ARF) (Acute Kidney Injury) report encloses the detailed analysis of Acute Renal Failure (ARF) (Acute Kidney Injury) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Acute Renal Failure (ARF) (Acute Kidney Injury) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Acute Renal Failure (ARF) (Acute Kidney Injury) treatment.

Acute Renal Failure (ARF) (Acute Kidney Injury) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Acute Renal Failure (ARF) (Acute Kidney Injury) treatment.

Acute Renal Failure (ARF) (Acute Kidney Injury) Market Outlook

The Acute Renal Failure (ARF) (Acute Kidney Injury) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Acute Renal Failure (ARF) (Acute Kidney Injury) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Acute Renal Failure (ARF) (Acute Kidney Injury) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Acute Renal Failure (ARF) (Acute Kidney Injury) market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Acute Renal Failure (ARF) (Acute Kidney Injury) market in 7MM.

The United States Market Outlook

This section provides the total Acute Renal Failure (ARF) (Acute Kidney Injury) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Acute Renal Failure (ARF) (Acute Kidney Injury) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Acute Renal Failure (ARF) (Acute Kidney Injury) market size and market size by therapies in Japan is also mentioned.

Acute Renal Failure (ARF) (Acute Kidney Injury) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Acute Renal Failure (ARF) (Acute Kidney Injury) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Acute Renal Failure (ARF) (Acute Kidney Injury) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Acute Renal Failure (ARF) (Acute Kidney Injury) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Acute Renal Failure (ARF) (Acute Kidney Injury) emerging therapies.

Reimbursement Scenario in Acute Renal Failure (ARF) (Acute Kidney Injury)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Acute Renal Failure (ARF) (Acute Kidney Injury) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Acute Renal Failure (ARF) (Acute Kidney Injury) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Acute Renal Failure (ARF) (Acute Kidney Injury) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Acute Renal Failure (ARF) (Acute Kidney Injury), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Acute Renal Failure (ARF) (Acute Kidney Injury) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Acute Renal Failure (ARF) (Acute Kidney Injury) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Acute Renal Failure (ARF) (Acute Kidney Injury) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acute Renal Failure (ARF) (Acute Kidney Injury) market

Report Highlights

  • In the coming years, Acute Renal Failure (ARF) (Acute Kidney Injury) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Acute Renal Failure (ARF) (Acute Kidney Injury) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Acute Renal Failure (ARF) (Acute Kidney Injury). Launch of emerging therapies will significantly impact the Acute Renal Failure (ARF) (Acute Kidney Injury) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Acute Renal Failure (ARF) (Acute Kidney Injury) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Analysis
  • Acute Renal Failure (ARF) (Acute Kidney Injury) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Acute Renal Failure (ARF) (Acute Kidney Injury) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Acute Renal Failure (ARF) (Acute Kidney Injury) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Acute Renal Failure (ARF) (Acute Kidney Injury) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Acute Renal Failure (ARF) (Acute Kidney Injury) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Acute Renal Failure (ARF) (Acute Kidney Injury) market size during the forecast period (2017-2030)?
  • At what CAGR, the Acute Renal Failure (ARF) (Acute Kidney Injury) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Acute Renal Failure (ARF) (Acute Kidney Injury) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Acute Renal Failure (ARF) (Acute Kidney Injury) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Acute Renal Failure (ARF) (Acute Kidney Injury)?
  • What is the historical Acute Renal Failure (ARF) (Acute Kidney Injury) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Acute Renal Failure (ARF) (Acute Kidney Injury) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Acute Renal Failure (ARF) (Acute Kidney Injury)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Acute Renal Failure (ARF) (Acute Kidney Injury) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Acute Renal Failure (ARF) (Acute Kidney Injury) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Acute Renal Failure (ARF) (Acute Kidney Injury) in the USA, Europe, and Japan?
  • What are the Acute Renal Failure (ARF) (Acute Kidney Injury) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Acute Renal Failure (ARF) (Acute Kidney Injury)?
  • How many therapies are developed by each company for Acute Renal Failure (ARF) (Acute Kidney Injury) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Acute Renal Failure (ARF) (Acute Kidney Injury) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Acute Renal Failure (ARF) (Acute Kidney Injury) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Acute Renal Failure (ARF) (Acute Kidney Injury) and their status?
  • What are the key designations that have been granted for the emerging therapies for Acute Renal Failure (ARF) (Acute Kidney Injury)?
  • What are the global historical and forecasted market of Acute Renal Failure (ARF) (Acute Kidney Injury)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Acute Renal Failure (ARF) (Acute Kidney Injury) market
  • To understand the future market competition in the Acute Renal Failure (ARF) (Acute Kidney Injury) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Acute Renal Failure (ARF) (Acute Kidney Injury) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Acute Renal Failure (ARF) (Acute Kidney Injury) market
  • To understand the future market competition in the Acute Renal Failure (ARF) (Acute Kidney Injury) market

Table of Contents

1. Key Insights

2. Executive Summary of Acute Renal Failure (ARF) (Acute Kidney Injury)

3. Competitive Intelligence Analysis for Acute Renal Failure (ARF) (Acute Kidney Injury)

4. Acute Renal Failure (ARF) (Acute Kidney Injury): Market Overview at a Glance

  • 4.1. Acute Renal Failure (ARF) (Acute Kidney Injury) Total Market Share (%) Distribution in 2017
  • 4.2. Acute Renal Failure (ARF) (Acute Kidney Injury) Total Market Share (%) Distribution in 2030

5. Acute Renal Failure (ARF) (Acute Kidney Injury): Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Acute Renal Failure (ARF) (Acute Kidney Injury) Treatment and Management
  • 8.2. Acute Renal Failure (ARF) (Acute Kidney Injury) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Acute Renal Failure (ARF) (Acute Kidney Injury) Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Acute Renal Failure (ARF) (Acute Kidney Injury): Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Acute Renal Failure (ARF) (Acute Kidney Injury) Market Size in 7MM
  • 13.3. Acute Renal Failure (ARF) (Acute Kidney Injury) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Acute Renal Failure (ARF) (Acute Kidney Injury) Total Market Size in the United States
    • 15.1.2. Acute Renal Failure (ARF) (Acute Kidney Injury) Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Acute Renal Failure (ARF) (Acute Kidney Injury) Total Market Size in Germany
    • 15.3.2. Acute Renal Failure (ARF) (Acute Kidney Injury) Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Acute Renal Failure (ARF) (Acute Kidney Injury) Total Market Size in France
    • 15.4.2. Acute Renal Failure (ARF) (Acute Kidney Injury) Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Acute Renal Failure (ARF) (Acute Kidney Injury) Total Market Size in Italy
    • 15.5.2. Acute Renal Failure (ARF) (Acute Kidney Injury) Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Acute Renal Failure (ARF) (Acute Kidney Injury) Total Market Size in Spain
    • 15.6.2. Acute Renal Failure (ARF) (Acute Kidney Injury) Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Acute Renal Failure (ARF) (Acute Kidney Injury) Total Market Size in the United Kingdom
    • 15.7.2. Acute Renal Failure (ARF) (Acute Kidney Injury) Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Acute Renal Failure (ARF) (Acute Kidney Injury) Total Market Size in Japan
    • 15.8.3. Acute Renal Failure (ARF) (Acute Kidney Injury) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Acute Renal Failure (ARF) (Acute Kidney Injury)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology (2017-2030)
  • Table 2 : 7MM Acute Renal Failure (ARF) (Acute Kidney Injury) Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Acute Renal Failure (ARF) (Acute Kidney Injury) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology in Germany (2017-2030)
  • Table 6 : Acute Renal Failure (ARF) (Acute Kidney Injury) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology in France (2017-2030)
  • Table 8 : Acute Renal Failure (ARF) (Acute Kidney Injury) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology in Italy (2017-2030)
  • Table 10 : Acute Renal Failure (ARF) (Acute Kidney Injury) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology in Spain (2017-2030)
  • Table 12 : Acute Renal Failure (ARF) (Acute Kidney Injury) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology in the UK (2017-2030)
  • Table 14 : Acute Renal Failure (ARF) (Acute Kidney Injury) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology in Japan (2017-2030)
  • Table 16 : Acute Renal Failure (ARF) (Acute Kidney Injury) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology (2017-2030)
  • Figure 2 : 7MM Acute Renal Failure (ARF) (Acute Kidney Injury) Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology in the United States (2017-2030)
  • Figure 4 : Acute Renal Failure (ARF) (Acute Kidney Injury) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology in Germany (2017-2030)
  • Figure 6 : Acute Renal Failure (ARF) (Acute Kidney Injury) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology in France (2017-2030)
  • Figure 8 : Acute Renal Failure (ARF) (Acute Kidney Injury) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology in Italy (2017-2030)
  • Figure 10 : Acute Renal Failure (ARF) (Acute Kidney Injury) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology in Spain (2017-2030)
  • Figure 12 : Acute Renal Failure (ARF) (Acute Kidney Injury) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology in the UK (2017-2030)
  • Figure 14 : Acute Renal Failure (ARF) (Acute Kidney Injury) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology in Japan (2017-2030)
  • Figure 16 : Acute Renal Failure (ARF) (Acute Kidney Injury) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)